Selective Serotonin Reuptake Inhibitors Increase Gastrointestinal but Not Other Site Bleeding Risk in Left...

Area of Science:

• Cardiology and Cardiovascular Surgery
• Pharmacology and Therapeutics
• Gastroenterology

Background:

• Left ventricular assist devices (LVADs) are crucial for end-stage heart failure management.
• Patients with LVADs often require psychotropic medications, including selective serotonin reuptuptake inhibitors (SSRIs), for comorbid conditions.
• Bleeding complications are a significant concern in LVAD patients, and the role of SSRIs in this risk profile requires elucidation.

Purpose of the Study:

• To investigate the association between SSRI use and bleeding complications in patients with LVADs.
• To specifically examine the impact of SSRIs on gastrointestinal (GI) bleeding risk.
• To assess the relationship between SSRI use and overall bleeding risk and international normalized ratio (INR) levels.

Main Methods:

• Systematic review and meta-analysis of observational studies.
• Included multicenter studies from tertiary care academic hospitals in the US and Europe.
• Analyzed data from 1,108 adult LVAD patients (431 on SSRIs, 677 controls).

Main Results:

• SSRI use was significantly associated with an increased risk of GI bleeding (Risk Ratio: 1.61, p=0.0019).
• Overall bleeding risk from any anatomical site did not reach statistical significance (Risk Ratio: 1.44, p=0.16).
• No significant difference in INR levels was observed at the time of GI bleeding (Mean Difference: 0.22, p=0.64).

Conclusions:

• SSRI therapy is linked to a significantly higher risk of gastrointestinal bleeding in LVAD patients.
• Findings underscore the importance of individualized bleeding risk assessment for LVAD patients on antidepressants.
• Consideration of gastrointestinal prophylaxis may be warranted for LVAD patients requiring SSRI therapy.